What is the recommended dosing of citalopram for adults with major depressive disorder, including adjustments for patients aged 60 years or older, hepatic impairment, pregnancy, and required washout after monoamine oxidase inhibitor use?

Citalopram Dosing for Major Depressive Disorder

For adults with major depressive disorder, initiate citalopram at 20 mg once daily, which is the recommended therapeutic dose for most patients; the maximum dose is 40 mg/day, but critical dose reductions to 20 mg/day maximum are mandatory for patients >60 years old, those with hepatic impairment, CYP2C19 poor metabolizers, and patients taking CYP2C19 inhibitors like cimetidine, due to significant QT prolongation risk. 1

Standard Adult Dosing

• Starting dose: 20 mg once daily
• Therapeutic dose: 20 mg/day is appropriate for most patients 1, 2
• Maximum dose: 40 mg/day 3, 1
• Dose titration: If inadequate response at 20 mg and patient tolerates medication well, may increase to 40 mg after adequate trial (typically 4-6 weeks) 2, 4

The evidence shows a relatively flat dose-response curve across 20-60 mg range, with 20 mg being the minimum effective dose 2. Higher doses (40-60 mg) showed more robust effects in moderate-to-severe depression 4, but must be balanced against cardiac safety concerns.

Critical Dose Restrictions (Maximum 20 mg/day)

Patients >60 Years Old

Maximum dose: 20 mg/day 5, 1

• Citalopram AUC increases by 23-30% and half-life increases by 30-50% in elderly patients 1
• This population has increased risk of QT prolongation and cardiac arrest (OR 1.21 for SSRIs) 5
• Greater risk of clinically significant hyponatremia 1

Hepatic Impairment

Maximum dose: 20 mg/day 1

• Oral clearance reduced by 37% and half-life doubled in hepatically impaired patients 1
• Significantly increased drug exposure necessitates dose limitation

CYP2C19 Poor Metabolizers

Maximum dose: 20 mg/day 1

• Steady-state Cmax increased by 68% and AUC by 107% 1
• Substantially elevated plasma concentrations increase QT prolongation risk

Patients Taking CYP2C19 Inhibitors

Maximum dose: 20 mg/day 1

• Includes cimetidine, omeprazole, and other potent CYP2C19 inhibitors
• Expected to decrease citalopram clearance significantly

MAOI Washout Requirements

Contraindicated: Do not use citalopram concomitantly with MAOIs or within 14 days of discontinuing MAOI treatment 3, 1

• Washout period: Allow at least 14 days after stopping MAOI before initiating citalopram
• Reverse washout: Allow at least 14 days after stopping citalopram before starting MAOI
• Rationale: Risk of life-threatening serotonin syndrome with combined use 3

Serotonin syndrome symptoms include mental status changes (agitation, confusion, delirium), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular symptoms (tremor, rigidity, hyperreflexia), and can progress to seizures, arrhythmias, and death 3, 1.

Pregnancy Considerations

No specific dose adjustment recommended, but treatment decision requires careful risk-benefit analysis 1

• Citalopram is excreted in breast milk; two reports of infant excessive somnolence, decreased feeding, and weight loss 1
• Women who discontinued antidepressants during pregnancy showed significant increase in depression relapse 1
• Decision must be individualized weighing risks of untreated depression versus potential fetal/neonatal effects
• Consider that untreated maternal depression carries substantial morbidity risks

Critical Safety Monitoring

QT Prolongation Risk

Citalopram causes dose-dependent QTc prolongation 5, 3, 5, 1:

• At 20 mg: mean QTcNi increase of 8.5 msec
• At 40 mg: predicted increase of 12.6 msec
• At 60 mg: mean increase of 18.5 msec
• Associated with Torsade de Pointes, ventricular tachycardia, and sudden death 3, 1

Contraindications for citalopram use:

• Congenital long QT syndrome
• Recent acute myocardial infarction
• Uncompensated heart failure
• Concurrent use of other QT-prolonging medications (Class IA/III antiarrhythmics, certain antipsychotics, antibiotics) 1

Monitoring requirements:

• Baseline ECG and electrolytes (potassium, magnesium) in at-risk patients
• Correct hypokalemia/hypomagnesemia before initiating treatment
• Periodic monitoring during treatment
• Discontinue if QTc >500 msec 1

Drug Interactions Beyond MAOIs

• Avoid combining with other serotonergic drugs (triptans, tramadol, fentanyl, lithium, St. John's Wort, amphetamines) due to serotonin syndrome risk 3, 1
• Citalopram has relatively low CYP450 interaction potential compared to other SSRIs 3

Treatment Duration

• Acute phase: 6-12 weeks to achieve response 6
• First episode: Minimum 4 months of continuation treatment after remission 7
• Recurrent depression: Consider prolonged maintenance treatment 7
• Long-term treatment (48+ weeks) effective in preventing recurrence in elderly patients 8

Common Pitfalls to Avoid

1. Exceeding 40 mg/day in general population - No additional efficacy, significantly increased cardiac risk
2. Using standard 40 mg dose in elderly patients - Must restrict to 20 mg maximum regardless of response
3. Inadequate MAOI washout - Fatal serotonin syndrome risk
4. Ignoring hepatic impairment - Requires mandatory dose reduction
5. Rapid discontinuation - Taper gradually to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, nausea) 3